3 news items
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
and three gynecological carcinomas – cervical, ovarian, and endometrial and is an ongoing Phase 1b/2 investigator led study at the MD Anderson Cancer
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
nor for participation in clinical trials of other investigational therapies.Mereo continues to actively engage
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
MREO
5 Mar 24
and is in an ongoing Phase 1b/2 investigator led study at the MD Anderson Cancer Center in clear cell ovarian cancer; navicixizumab, for the treatment
- Prev
- 1
- Next